UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41615 Mangoceuticals, Inc. (Exact name of Registrant as specified in its charter) Common Stock, par value $0.0001 per share ...

Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform,, is pleased to announce it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit, which will be taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 22nd to Wednesday, October 23rd, 2024, in Nassau, Bahamas. Jacob Cohen, Founder and CEO, is scheduled t ...

公司基本信息 - 公司股票在纳斯达克资本市场交易，股票代码为MGRX[8] - 公司被认定为新兴增长公司[9] - 公司未选择使用延长过渡期以遵守新的或修订的财务会计标准[10] - 公司注册地址位于德克萨斯州达拉斯市，电话号码为(214) 242-9619[5][6] - 公司注册文件编号为001-41615，IRS雇主识别号为87-3841292[3] 财务报告信息 - 公司发布2024年8月15日的财务报告，涵盖截至2024年6月30日的三个月和六个月[11] - 公司报告日期为2024年8月14日[1] 声明与披露 - 公司包含前瞻性声明，涉及未来财务表现、事件和趋势，这些声明受制于不确定性和风险[15] - 公司财务信息和展品不视为“提交”给证券交易委员会，除非有明确引用[12] 网站信息 - 公司网站地址仅作为非活跃文本参考，不构成活跃超链接[14]

Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues. During the six months e ...

产品和服务 - 公司通过网站www.MangoRx.com为消费者提供远程医疗服务，并提供处方药在线配送[77] - 公司主要产品包括治疗勃起功能障碍的Mango ED、促进毛发生长的Mango GROW以及口服睾酮替代疗法产品PRIME[77] - 公司以603A法案的豁免条款生产和销售Mango ED和Mango GROW产品[77] - 公司将利用收购的专利开展研发、临床试验和功效测试,用于开发口服溶解片、含片和漱口水等产品[79] 业务拓展 - 公司以2,000万美元的价格收购了Intramont Technologies公司的相关专利[79] - 公司与Intramont Technologies公司签订了专利授权反向许可协议,Intramont需支付专利使用的10%销售提成[79] - 公司与ISFLST签订了为期3年的主分销协议，ISFLST将在亚太和拉丁美洲地区销售公司的MangoRx Grow和Mango ED产品[81] - 公司计划在未来12个月内继续采用相同的营销和管理策略，提供优质产品和客户服务，同时寻求通过收购来有机扩张业务[81] 财务状况 - 公司目前有0.9百万美元的营运赤字，预计未来12个月内需要额外融资以维持当前运营水平和支付公众公司的相关费用[81] - 公司在2024年第二季度的收入为163,163美元，同比增长15.5%[83] - 公司2024年第二季度的总营业费用为850,704美元，同比增加264,662美元，主要是由于法律费用、软件开发费用和股份支付费用的增加[83,84] - 公司2024年上半年的收入为377,258美元，同比增长55.9%[85,86] - 公司2024年上半年的总营业费用为1,622,662美元，同比减少347,339美元，主要是由于法律费用、配售代理费和投资者关系费用的减少[87] - 公司2024年上半年的净亏损为4,758,560美元，同比减少86,350美元[87] - 截至2024年6月30日，公司现金余额为490,243美元，较2023年12月31日的739,006美元有所下降[88] - 截至2024年6月30日，公司总流动负债为1,378,265美元，包括718,650美元的应付账款和应计负债[88] - 截至2024年6月30日，公司有900万美元的营运资金缺口和15,986,733美元的累计亏损[88] - 公司主要依靠关联方贷款、股票发行以及产品销售收入来支持运营[88] - 公司预计未来将继续大幅投入运营开支以拓展产品和吸引客户，可能无法实现盈利[88] 融资活动 - 公司于2023年3月完成首次公开发行,募集资金约500万美元[92] - 公司于2023年12月完成跟进公开发行,募集资金约120万美元[93] - 公司还向承销商授予认股权证[92][93][94] - 公司与机构投资者签订了证券购买协议，出售1,500股B系列可转换优先股和3,300,000份认股权证，总价值2,500,000美元[95] - 公司分四次完成了B系列优先股的发行,总计发行2,750,000股,并配发4,800,000份认股权证[95] - 公司与投资者签订了股权融资协议,投资者承诺最高可提供2,500万美元的股权融资,公司已经通过该协议融资457,655美元[99,100] - 公司需要额外的资金支持未来12个月的运营,可能通过债务或股权融资的方式筹集资金,但未来融资可能会导致股东权益被稀释[101] - 公司已经为认股权证和B系列优先股的转换保留了5,000万股的普通股[95] 会计政策和披露 - 公司财务报表的编制需要管理层做出重大判断和假设，实际结果可能与估计存在差异[102] - 股权激励费用的确认需要根据授予日的公允价值计量，涉及多个复杂变量的估计[102] - 公司普通股期权和认股权证的会计处理需要根据其是否满足权益工具分类的条件[103] - 公司选择采用JOBS法案下的豁免条款，延迟执行新的会计准则[104] - 公司将采用新的报告分部信息披露准则和所得税信息披露准则[105] - 公司作为小型报告公司无需提供市场风险的定量和定性披露[106]

Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a leader in men's health and wellness products including erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce the initiation of efficacy studies on its patented respiratory illness prevention technology in collaboration with Vipragen Biosciences and IntraMont Technologies, Inc. Notably, these trials have been pre-funded, ensuring that the ...

DALLAS, TEXAS, July 18, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is pleased to announce that its CEO, Jacob Cohen, was recently featured on Benzinga All-Access. CLICK HERE TO WATCH THE COMPLETE INTERVIEW. In the interview with Zunaid Suleman, Cohen discu ...

DALLAS, TEXAS, July 18, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is pleased to announce that its CEO, Jacob Cohen, was recently featured on Benzinga All-Access. CLICK HERE TO WATCH THE COMPLETE INTERVIEW. In the interview with Zunaid Suleman, Cohen discu ...

DALLAS, TX, July 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce obtaining DEA authorization for the company's groundbreaking HIPAA-compliant operating system through Surescripts. This significant milestone positions MangoRx at the for ...

DALLAS, TX, July 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce obtaining DEA authorization for the company’s groundbreaking HIPAA-compliant operating system through Surescripts. This significant milestone positions MangoRx at the fo ...